Immuno-Oncology | Specialty

Dr. Figlin on Considerations for Combining TKIs and Immunotherapy in RCC

January 10th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Checkpoint Inhibitors Herald New Era in Urothelial Cancer

January 9th 2019

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

Treatment Breakthroughs Advance Care Across Heterogeneous NSCLC Population

January 8th 2019

Kwok-Kin Wong, MD, PhD, discusses updates in non–small cell lung cancer and the importance of enrolling patients in clinical trials to further progress the field.

Bellmunt Addresses Immunotherapy Advances, Challenges in Bladder Cancer

January 8th 2019

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Closer Study Required of Immunological Differences Between Sexes

January 7th 2019

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

Dr. Perez-Soler on Immunotherapy Advances in SCLC

January 7th 2019

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses recent advances in immunotherapy for the treatment of patients with small cell lung cancer.

Finding a Place for Stimulatory Immune Checkpoint Antibodies

January 7th 2019

When it works, immunotherapy can dramatically outperform standard of care—for some cancer types, in ways thought unattainable a decade ago.

Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer

January 4th 2019

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Forde Forecasts Future Use of Immunotherapy in Early-Stage NSCLC

January 4th 2019

Patrick M. Forde, MBBCh, discusses the future of immunotherapy in early-stage non–small cell lung cancer.

Expert Reflects on 2018 Lung Cancer Advancements

January 2nd 2019

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

Immunotherapy Advances SCLC Treatment Landscape

December 27th 2018

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

Biomarker Hunt Focuses on Predicting Immunotherapy Adverse Events

December 26th 2018

Although the need for biomarkers of immunotherapy response has generated much attention, investigators also are pursuing mechanisms for distinguishing which patients will experience adverse effects from these therapies.

FDA Delays Decision on Frontline Pembrolizumab sBLA in NSCLC

December 21st 2018

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Dr. Overman on Next Steps With Immunotherapy in mCRC

December 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

Dr. Brahmer on Biomarkers for Immune Response in NSCLC

December 18th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.

Dr. Grivas on Mechanisms of Immune Response in Bladder Cancer

December 18th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.

Expert Highlights Utility of PD-L1 to Select Immunotherapy in NSCLC

December 14th 2018

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Powles Navigates Rapidly Evolving Frontline Paradigm in Urothelial Carcinoma

December 13th 2018

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Real-World Findings Support Nivolumab Use in HNSCC

December 12th 2018

Nivolumab demonstrated durable response and overall survival rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Choueiri on Next Steps for Treatment in RCC

December 12th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses next steps for treatment in renal cell carcinoma.